Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema
German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...
GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced the completion of its acquisition of BP Asset IX, a...
Qilu Pharmaceutical Partners with Sagent Pharmaceuticals to Expand US Market Presence
China-based Qilu Pharmaceutical Co., Ltd. this week announced a strategic partnership with US-headquartered Sagent Pharmaceuticals....
NMPA Releases 93rd Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 93rd batch of reference drugs for...
Roche’s Chugai Pharmaceutical Partners with Gero to Develop Therapies for Age-Related Diseases
Roche’s Japan-based subsidiary Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced this week a joint research...
CStone Pharmaceuticals Licenses Cejemly to Istituto Gentili for 23 Countries in Europe and the UK
China-based CStone Pharmaceuticals (HKG: 2616) announced a licensing agreement with Istituto Gentili S.R.L., granting the...
Jiangsu CTTQ’s TQB2102 Receives Breakthrough Therapy Designation for HER2+ Breast Cancer
Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
Wepon Medical Receives NMPA Clinical Approval for WP107 in Generalized Myasthenia Gravis
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that it has received clinical approval...
China’s CDE Announces 95th Batch of Reference Preparations for Public Comment
China’s Center for Drug Evaluation (CDE) has released the 95th batch of reference preparations for...
China Ministry of Finance Restricts EU-Imported Medical Devices in Government Procurement Over RMB45 Million
China’s Ministry of Finance (MoF) has issued the “Notice on Implementing Relevant Measures for EU-Imported...
SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study
China’s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG...
BGI Genomics Launches Mini Breast Cancer 76-Gene Detection System for Personalized Treatment
China-based BGI Genomics Co., Ltd (SHE: 300676) announced the launch of its mini breast cancer...
AstraZeneca’s Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European...
Modella AI Collaborates with AstraZeneca to Accelerate Oncology Drug Development with AI
US-based Modella AI, a leader in biomedical artificial intelligence (AI), announced a multi-year collaboration with...
CStone Pharmaceuticals Announces Phase III Trial Progress for Nofazinlimab in Hepatocellular Carcinoma
China-based CStone Pharmaceuticals (HKG: 2616) announced the latest progress in its global multicenter Phase III...
Micot Raises Over RMB 100 Million in Series D Funding Led by Zheshang Venture Capital
Micot, a polypeptide new molecular entity (NME) drug developer with operations in mainland China, Hong...
NMPA Unveils Measures to Support High-End Medical Device Innovation with Full Lifecycle Regulation
China’s National Medical Products Administration (NMPA) last week released the “Measures to Optimize Full-lifecycle Regulation...
AstraZeneca in Talks for $15B Licensing Deal for Ivonescimab with Summit Therapeutics
UK-based AstraZeneca plc (AZ, NASDAQ: AZN) is reportedly in negotiations with Summit Therapeutics, the US...
Jiangsu Vcare PharmaTech’s VC004 NDA Accepted for Review by China’s NMPA
China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004...
Novartis’ Cosentyx Fails to Meet Primary Endpoint in GCAptAIN Study for Giant Cell Arteritis
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced this week that its Phase III GCAptAIN study...